Abstract
Although cardiovascular disease is the leading cause of death and major disability in older adults, older patients have been consistently under-represented in most cardiovascular clinical trials. This article summarizes the results of four trials published from 2020 to 2022 with practice-changing implications directly applicable to the care of older adults. The key findings from these trials were that: (1) an initial conservative approach to managing selected patients with stable ischemic heart disease is reasonable, even in the setting of moderate or severe ischemia; (2) empagliflozin is effective in reducing heart failure hospitalizations in patients with heart failure and preserved ejection fraction, with or without diabetes; (3) an individually tailored physical rehabilitation program reduces deconditioning and functional decline in older patients hospitalized with heart failure; and (4) restricting dietary sodium intake to less than 1500 mg/day is unlikely to improve outcomes in most patients with heart failure.
Original language | English |
---|---|
Pages (from-to) | 1021-1027 |
Number of pages | 7 |
Journal | Journal of the American Geriatrics Society |
Volume | 71 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2023 |
Keywords
- cardiology
- heart failure
- ischemic heart disease
- rehabilitation
- sodium-glucose cotransporter-2 (SGLT2) inhibitors